Months after pulling only drug from US, Oncopeptides takes back withdrawal request — but stays mum on why

What happens when you pull a request to pull your drug from the market?

Oncopeptides is trying to find out, revealing late Friday that it has contacted the FDA and rescinded a letter it sent back in October, requesting voluntary withdrawal of the NDA of its multiple myeloma drug, Pepaxto, in the US — the only place where it’s approved.